LUNG vs PATH
Pulmonx Corp (LUNG) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Pulmonx Corp (LUNG) is a medical devices company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported LUNG revenue for 2024-12-31 was $83.8M. Net income was -$56.4M. Revenue was up 22.0% from 2023-12-31 to 2024-12-31. LUNG currently screens at market cap $111.9M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
LUNG currently screens at market cap $111.9M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the LUNG and PATH stock pages for the full models.
Not investment advice.